Background: Renal ischemia—reperfusion (RIR) is an important etiopathological mechanism
of acute renal failure (ARF). Erythropoietin (EPO) has been candidate as a nephroprotectant
agent. However, its nephroprotective effect when it is accompanied with estrogen has not been studied
in female.
Methods: Fifty-six female rats were divided into seven groups. Each formed of 8 rats. Group I:
control group. Group 11: Female rats exposed to RIR (named RIR group).Group III: Female rats
exposed to RIR and pretreated with EPO (named RIR + EPO group). Group IV: ovariectomized
rats exposed to RIR (named OVR + RIR group). Group V: ovariectomized rats received estrogen
(E) then exposed to RIR (named OVR + RIR + E group). Group VI: ovariectomized rats received
EPO before RIR (named OVR + RIR + EPO group). Group VII: ovariectomized rats received E
then received EPO before RIR (named OVR + RIR + E + EPO group).Serum creatinine, blood
urea nitrogen (BUN) and renal blood flow (RBF) were measured. Tumor necrosis factor-a
(TNE-ct). Myeloperoxidase activity (MPO), nitric oxide (NO), endothelin- I(ET-1) and EPO levels
were assessed in the renal tissue. Histopathology was assessed to detect renal damage score.
Results: RIR significantly increased the serum levels of creatinine and BUN with decrease in RBF.
In addition it significantly increased TNF-a, MPO and endothelin-1 levels with decrease in NO and
EPO levels in renal tissue. However, these parameters significantly reversed by EPO except RBF.
Combination of E and EPO leads to significant decrease in the protective effect of FPO.
Conclusion: It seems that EPO could protect the kidney against RIR, while this protective effect
was decreased when E was supplemented.
0 2015 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (Imp: tleativecommons.orgilicenses,tby-ne-nd..4.0 ). |
